Articles - 1fvt mentioned but not cited (6)
- In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug. Shi XN, Li H, Yao H, Liu X, Li L, Leung KS, Kung HF, Lu D, Wong MH, Lin MC. PLoS One 10 e0132072 (2015)
- Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies. Eldehna WM, Al-Rashood ST, Al-Warhi T, Eskandrani RO, Alharbi A, El Kerdawy AM. J Enzyme Inhib Med Chem 36 270-285 (2021)
- A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights. Al-Sanea MM, Obaidullah AJ, Shaker ME, Chilingaryan G, Alanazi MM, Alsaif NA, Alkahtani HM, Alsubaie SA, Abdelgawad MA. Molecules 26 E412 (2021)
- Crystal structure of human cyclin-dependent kinase-2 complex with MK2 inhibitor TEI-I01800: insight into the selectivity. Fujino A, Fukushima K, Kubota T, Kosugi T, Takimoto-Kamimura M. J Synchrotron Radiat 20 905-909 (2013)
- Evaluation of Zamia floridana A. DC. Leaves and Its Isolated Secondary Metabolites as Natural Anti-Toxoplasma and Anti-Cancer Agents Using In Vitro and In Silico Studies. El-Seadawy HM, Abo El-Seoud KA, El-Aasr M, Tawfik HO, Eldehna WM, Ragab AE. Metabolites 13 10 (2022)
- Discovery of Kinase and Carbonic Anhydrase Dual Inhibitors by Machine Learning Classification and Experiments. Kim MJ, Pandit S, Jee JG. Pharmaceuticals (Basel) 15 236 (2022)
Reviews citing this publication (29)
- GSK3 takes centre stage more than 20 years after its discovery. Frame S, Cohen P. Biochem J 359 1-16 (2001)
- The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Vermeulen K, Van Bockstaele DR, Berneman ZN. Cell Prolif 36 131-149 (2003)
- GSK3 inhibitors: development and therapeutic potential. Cohen P, Goedert M. Nat Rev Drug Discov 3 479-487 (2004)
- Cyclin D-dependent kinases, INK4 inhibitors and cancer. Ortega S, Malumbres M, Barbacid M. Biochim Biophys Acta 1602 73-87 (2002)
- Pharmacological inhibitors of cyclin-dependent kinases. Knockaert M, Greengard P, Meijer L. Trends Pharmacol Sci 23 417-425 (2002)
- Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Zhou BB, Bartek J. Nat Rev Cancer 4 216-225 (2004)
- In search of the "hair cycle clock": a guided tour. Paus R, Foitzik K. Differentiation 72 489-511 (2004)
- Towards a molecular understanding of hair loss and its treatment. Cotsarelis G, Millar SE. Trends Mol Med 7 293-301 (2001)
- Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Peyressatre M, Prével C, Pellerano M, Morris MC. Cancers (Basel) 7 179-237 (2015)
- Chemotherapy-induced alopecia. Trüeb RM. Semin Cutan Med Surg 28 11-14 (2009)
- Prevention of chemotherapy-induced hair loss by scalp cooling. Grevelman EG, Breed WP. Ann Oncol 16 352-358 (2005)
- Complexities in the development of cyclin-dependent kinase inhibitor drugs. Sausville EA. Trends Mol Med 8 S32-7 (2002)
- Recent advances in chemical approaches to the study of biological systems. Shogren-Knaak MA, Alaimo PJ, Shokat KM. Annu Rev Cell Dev Biol 17 405-433 (2001)
- Structural aspects of protein kinase control-role of conformational flexibility. Engh RA, Bossemeyer D. Pharmacol Ther 93 99-111 (2002)
- Structure-based design of cyclin-dependent kinase inhibitors. Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble ME. Pharmacol Ther 93 125-133 (2002)
- Molecular mechanisms of chemotherapy-induced hair loss. Botchkarev VA. J Investig Dermatol Symp Proc 8 72-75 (2003)
- Designing inhibitors of cyclin-dependent kinases. Hardcastle IR, Golding BT, Griffin RJ. Annu Rev Pharmacol Toxicol 42 325-348 (2002)
- CDKs and CKIs: molecular targets for tissue remodelling. Nabel EG. Nat Rev Drug Discov 1 587-598 (2002)
- Selectivity and potency of cyclin-dependent kinase inhibitors. Sridhar J, Akula N, Pattabiraman N. AAPS J 8 E204-21 (2006)
- The A-type cyclins and the meiotic cell cycle in mammalian male germ cells. Wolgemuth DJ, Lele KM, Jobanputra V, Salazar G. Int J Androl 27 192-199 (2004)
- Progress toward the development of agents to modulate the cell cycle. Toogood PL. Curr Opin Chem Biol 6 472-478 (2002)
- Treatment of chemotherapy-induced alopecia. Yeager CE, Olsen EA. Dermatol Ther 24 432-442 (2011)
- Perspectives for cancer therapies with cdk2 inhibitors. Wadler S. Drug Resist Updat 4 347-367 (2001)
- Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development. Waters NC, Geyer JA. Expert Opin Ther Targets 7 7-17 (2003)
- Design of new anticancer therapies targeting cell cycle checkpoint pathways. Sampath D, Plunkett W. Curr Opin Oncol 13 484-490 (2001)
- Chemotherapy-induced alopecia. Trüeb RM. Curr Opin Support Palliat Care 4 281-284 (2010)
- Prevention and Treatment of Chemotherapy-Induced Alopecia. Rossi A, Caro G, Fortuna MC, Pigliacelli F, D'Arino A, Carlesimo M. Dermatol Pract Concept 10 e2020074 (2020)
- Library screening by fragment-based docking. Huang D, Caflisch A. J Mol Recognit 23 183-193 (2010)
- 3-Hydrazinoindolin-2-one derivatives: Chemical classification and investigation of their targets as anticancer agents. Ibrahim HS, Abou-Seri SM, Abdel-Aziz HA. Eur J Med Chem 122 366-381 (2016)
Articles citing this publication (47)
- Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Pierson-Mullany LK, Lange CA. Mol Cell Biol 24 10542-10557 (2004)
- Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. Kumar A, Mandiyan V, Suzuki Y, Zhang C, Rice J, Tsai J, Artis DR, Ibrahim P, Bremer R. J Mol Biol 348 183-193 (2005)
- High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations. Okimoto N, Futatsugi N, Fuji H, Suenaga A, Morimoto G, Yanai R, Ohno Y, Narumi T, Taiji M. PLoS Comput Biol 5 e1000528 (2009)
- Prevention of β-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events. Xu X, Lei Y, Luo J, Wang J, Zhang S, Yang XJ, Sun M, Nuwaysir E, Fan G, Zhao J, Lei L, Zhong Z. Stem Cell Res 10 213-227 (2013)
- The crystal structure of human CDK7 and its protein recognition properties. Lolli G, Lowe ED, Brown NR, Johnson LN. Structure 12 2067-2079 (2004)
- Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Moon MJ, Lee SK, Lee JW, Song WK, Kim SW, Kim JI, Cho C, Choi SJ, Kim YC. Bioorg Med Chem 14 237-246 (2006)
- A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. Patel Y, Gillet VJ, Bravi G, Leach AR. J Comput Aided Mol Des 16 653-681 (2002)
- Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Villerbu N, Gaben AM, Redeuilh G, Mester J. Int J Cancer 97 761-769 (2002)
- Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs. Johnson K, Liu L, Majdzadeh N, Chavez C, Chin PC, Morrison B, Wang L, Park J, Chugh P, Chen HM, D'Mello SR. J Neurochem 93 538-548 (2005)
- Glycogen synthase kinase-3 regulates IGFBP-1 gene transcription through the thymine-rich insulin response element. Finlay D, Patel S, Dickson LM, Shpiro N, Marquez R, Rhodes CJ, Sutherland C. BMC Mol Biol 5 15 (2004)
- A chemical compound commonly used to inhibit PKR, {8-(imidazol-4-ylmethylene)-6H-azolidino[5,4-g] benzothiazol-7-one}, protects neurons by inhibiting cyclin-dependent kinase. Chen HM, Wang L, D'Mello SR. Eur J Neurosci 28 2003-2016 (2008)
- Conservation of orientation and sequence in protein domain--domain interactions. Littler SJ, Hubbard SJ. J Mol Biol 345 1265-1279 (2005)
- Effect of adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth in mice with chemotherapy-induced alopecia. Sato N, Leopold PL, Crystal RG. J Natl Cancer Inst 93 1858-1864 (2001)
- Purified brominated indole derivatives from Dicathais orbita induce apoptosis and cell cycle arrest in colorectal cancer cell lines. Esmaeelian B, Benkendorff K, Johnston MR, Abbott CA. Mar Drugs 11 3802-3822 (2013)
- Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Betticher DC, Delmore G, Breitenstein U, Anchisi S, Zimmerli-Schwab B, Müller A, von Moos R, Hügli-Dayer AM, Schefer H, Bodenmann S, Bühler V, Trueb RR. Support Care Cancer 21 2565-2573 (2013)
- Computational chemistry approach to protein kinase recognition using 3D stochastic van der Waals spectral moments. González-Díaz H, Saíz-Urra L, Molina R, González-Díaz Y, Sánchez-González A. J Comput Chem 28 1042-1048 (2007)
- Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Kontopidis G, McInnes C, Pandalaneni SR, McNae I, Gibson D, Mezna M, Thomas M, Wood G, Wang S, Walkinshaw MD, Fischer PM. Chem Biol 13 201-211 (2006)
- SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Moshinsky DJ, Bellamacina CR, Boisvert DC, Huang P, Hui T, Jancarik J, Kim SH, Rice AG. Biochem Biophys Res Commun 310 1026-1031 (2003)
- CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia. Purba TS, Ng'andu K, Brunken L, Smart E, Mitchell E, Hassan N, O'Brien A, Mellor C, Jackson J, Shahmalak A, Paus R. EMBO Mol Med 11 e11031 (2019)
- Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells. Schmidt M, Fan Z. Oncogene 20 6164-6171 (2001)
- S phase entry causes homocysteine-induced death while ataxia telangiectasia and Rad3 related protein functions anti-apoptotically to protect neurons. Ye W, Blain SW. Brain 133 2295-2312 (2010)
- Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. Ojo KK, Arakaki TL, Napuli AJ, Inampudi KK, Keyloun KR, Zhang L, Hol WG, Verlinde CL, Merritt EA, Van Voorhis WC. Mol Biochem Parasitol 176 98-108 (2011)
- Pathogenesis and treatment options for chemotherapy-induced alopecia: a systematic review. Rubio-Gonzalez B, Juhász M, Fortman J, Mesinkovska NA. Int J Dermatol 57 1417-1424 (2018)
- DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex. Nakajima W, Sharma K, Lee JY, Maxim NT, Hicks MA, Vu TT, Luu A, Yeudall WA, Tanaka N, Harada H. Oncotarget 7 36353-36365 (2016)
- Cytotoxic activity and molecular docking of a novel biflavonoid isolated from Jacaranda acutifolia (Bignoniaceae). Mostafa NM, Ashour ML, Eldahshan OA, Singab AN. Nat Prod Res 30 2093-2100 (2016)
- Structure-activity relationship study of oxindole-based inhibitors of cyclin-dependent kinases based on least-squares support vector machines. Li J, Liu H, Yao X, Liu M, Hu Z, Fan B. Anal Chim Acta 581 333-342 (2007)
- Topochemical models for prediction of cyclin-dependent kinase 2 inhibitory activity of indole-2-ones. Dureja H, Madan AK. J Mol Model 11 525-531 (2005)
- 3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors. Liu JJ, Dermatakis A, Lukacs C, Konzelmann F, Chen Y, Kammlott U, Depinto W, Yang H, Yin X, Chen Y, Schutt A, Simcox ME, Luk KC. Bioorg Med Chem Lett 13 2465-2468 (2003)
- Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain. Katikaneni R, Ponnapakkam T, Suda H, Miyata S, Sakon J, Matsushita O, Gensure RC. Int J Cancer 131 E813-21 (2012)
- Chk1 has an essential role in the survival of differentiated cortical neurons in the absence of DNA damage. Ye W, Blain SW. Apoptosis 16 449-459 (2011)
- Cyclin-dependent kinase inhibitors block erythrocyte invasion and intraerythrocytic development of Babesia bovis in vitro. Nakamura K, Yokoyama N, Igarashi I. Parasitology 134 1347-1353 (2007)
- Semi-synthetic aristolactams--inhibitors of CDK2 enzyme. Hegde VR, Borges S, Pu H, Patel M, Gullo VP, Wu B, Kirschmeier P, Williams MJ, Madison V, Fischmann T, Chan TM. Bioorg Med Chem Lett 20 1384-1387 (2010)
- The preventive effect of vitamin D3 on radiation-induced hair toxicity in a rat model. Baltalarli B, Bir F, Demirkan N, Abban G. Life Sci 78 1646-1651 (2006)
- Feature-map vectors: a new class of informative descriptors for computational drug discovery. Landrum GA, Penzotti JE, Putta S. J Comput Aided Mol Des 20 751-762 (2006)
- Laminin-511, inducer of hair growth, is down-regulated and its suppressor in hair growth, laminin-332 up-regulated in chemotherapy-induced alopecia. Imanishi H, Tsuruta D, Tateishi C, Sugawara K, Paus R, Tsuji T, Ishii M, Ikeda K, Kunimoto H, Nakajima K, Jones JC, Kobayashi H. J Dermatol Sci 58 43-54 (2010)
- Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors. Vulpetti A, Casale E, Roletto F, Amici R, Villa M, Pevarello P. J Mol Graph Model 24 341-348 (2006)
- Chemoprevention of doxorubicin-induced alopecia in mice by dietary administration of L-cystine and vitamin B6. D'Agostini F, Fiallo P, Ghio M, De Flora S. Arch Dermatol Res 305 25-34 (2013)
- Flexi-pharma: a molecule-ranking strategy for virtual screening using pharmacophores from ligand-free conformational ensembles. Lans I, Palacio-Rodríguez K, Cavasotto CN, Cossio P. J Comput Aided Mol Des 34 1063-1077 (2020)
- A study on the extracts of Cuscuta reflexa Roxb. in treatment of cyclophosphamide induced alopecia. Patel S, Sharma V, Sharma V, Chauhan NS, Dixit VK. Daru 22 7 (2014)
- Spy1 Protein Mediates Phosphorylation and Degradation of SCG10 Protein in Axonal Degeneration. Liu Y, Wang Y, Chen Y, Li X, Yang J, Liu Y, Shen A. J Biol Chem 290 13888-13894 (2015)
- Synthesis and Evaluation of Some New 4H-Pyran Derivatives as Antioxidant, Antibacterial and Anti-HCT-116 Cells of CRC, with Molecular Docking, Antiproliferative, Apoptotic and ADME Investigations. El-Sayed NNE, Zaki MEA, Al-Hussain SA, Ben Bacha A, Ben Bacha A, Berredjem M, Masand VH, Almarhoon ZM, Omar HS. Pharmaceuticals (Basel) 15 891 (2022)
- Association between alopecia and response to chemotherapy in patients with Hodgkin lymphoma. Elis A, Blickstein D, Manor Y, Lishner M. Ther Drug Monit 27 287-289 (2005)
- Practical applications of matched series analysis: SAR transfer, binding mode suggestion and data point validation. Hunt P, Segall M, O'Boyle N, Sayle R. Future Med Chem 9 153-168 (2017)
- Mapping protein pockets through their potential small-molecule binding volumes: QSCD applied to biological protein structures. Mason K, Patel NM, Ledel A, Moallemi CC, Wintner EA. J Comput Aided Mol Des 18 55-70 (2004)
- Novel 4-(4-substituted-thiazol-2-ylamino)-N-(pyridin-2-yl)-benzenesulfonamides as cytotoxic and radiosensitizing agents. Ghorab MM, Ragab FA, Heiba HI, Agha HM, Nissan YM. Arch Pharm Res 35 59-68 (2012)
- PEP8-TAT2, a membrane-permeable peptide, inhibits cyclin-Cdk2 activity in HeLa cells. Chun KH, Kim DK, Nam YW, Lee SK. Cancer Lett 213 223-230 (2004)
- Lability in sulfur acidic cultivation medium explains unstable effects of CDK inhibitors on Cyanidioschyzon merolae cell proliferation. Kobayashi Y, Tanaka K. J Gen Appl Microbiol 64 299-302 (2019)